Device Trial Radar · NCT05818098
Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR)
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Mar 29, 2023
Primary completion
Sep 15, 2023
Study completion Sep 15, 2023
Sponsor
- Lead sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- The Second Affiliated Hospital of Harbin Medical University; Huai'an First People's Hospital; People's Hospital of Xinjiang Uygur Autonomous Region; First Affiliated Hospital Xi'an Jiaotong University; West China Hospital; Wuhan Central Hospital; First Hospital of China Medical University; Shanxi Bethune Hospital; Hebei Provincial People's Hospital; The Second Hospital of Hebei Medical University; Shanxi Cardiovascular Hospital; Shengjing Hospital; Three Gorges Hospital of Chongqing University; The First Hospital of Jilin University; Xiamen Cardiovascular Hospital, Xiamen University; The People's Hospital of Liaoning Province; Shanghai East Hospital; Linfen No.4 People's Hospital
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary intravascular lithotripsy system for the treatment of patients with coronary calcification.
Conditions
- Coronary Artery Calcification
Interventions
Intravascular Lithotripsy System of Shanghai MicroPort RhythmDevice
The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Procedure success rateTime frame: During hospitalization (up to 7 days after procedure)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affliated Hospital Ha'erbin Medical University
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.